Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854442 | 0.78 | P2RX7 (0.33) | CA12CA1CA2CA9CA14 | |
| SCHEMBL17809517 | 0.78 | IDO1 (0.35) | CA12CA1CA2CA9OPRM1 | |
| SCHEMBL31381659 | 0.77 | CYP1A2 (0.40) | OPRM1OPRL1CYP1A2CYP3A4TGFBR1 | |
| SCHEMBL31419562 | 0.76 | CYP2A6 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9113104 | 0.75 | GSR (0.41) | KDM4EMAPTNPSR1KMT2A | |
| SCHEMBL30527437 | 0.73 | CA12 (0.60) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30854385 | 0.71 | MYC (0.45) | IDO1CCR9P2RX7KDM4EMAPT | |
| SCHEMBL31419628 | 0.71 | KDM5B (0.39) | OPRM1OPRL1TDP1CYP1A2CYP3A4 | |
| SCHEMBL31419636 | 0.71 | KCNJ5 (0.32) | GRM4 | |
| SCHEMBL30555542 | 0.70 | MYC (0.39) | TDP1KDM4EMAPTMYCNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125891-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-118510776-A | Five-membered ring-containing derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-116178345-B | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4367099-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024046327-A1 | P38α-MK2 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-116178345-A | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4125891-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023283338-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-9365546-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365547-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | CA12 4878/4885CA1 4867/4885CA2 4778/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | CA12 2924/4885CA1 2854/4885CA2 1573/4885 |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | CA12 4878/4885CA1 4867/4885CA2 4778/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | CA12 2565/4885CA1 1709/4885CA2 2220/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | CA12 2601/4885CA1 3101/4885CA2 1270/4885 |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | CA12 4878/4885CA1 4867/4885CA2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.